Maximizing the therapeutic benefit of NAT calls for intensified validation of the prognostic impact but even clinically applied prognostic features suffer from lack of reliable threshold values, especially in distinct breast cancer subtypes [29]. This evidence concerns the gene BRD2 and breast carcinoma.